July 2, 2019
FSD Pharma Closes Deal to Acquire Prismic Pharmaceuticals
FSD acquires platform company to advance R&D of targeted application of micro-Palmitoylethanolamide impacting the human endocannabinoid system
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
July 2, 2019
Teva Presents Positive Results Showing Improvement in Disability and Quality of Life from the Phase IIIb FOCUS study of Fremanezumab in Adults with Migraine
These results include reduction in monthly average migraine days; reduction in migraine related symptoms; and improvements in depression status; work productivity and activity impairment.
July 2, 2019
ZULRESSO Launched by Sage Therapeutics, 11th FDA-approved drug to use Ligand’s Captisol technology
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that Sage Therapeutics has launched ZULRESSO™ (brexanolone) injection, which was approved by the U.S. Food and Drug Administration (FDA) on March 19, 2019, and is the first and only treatment specifically approved for postpartum depression (PPD), one of the most common medical complications during and after pregnancy.
July 2, 2019
Pfizer Completes Acquisition of Therachon
Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG.
July 2, 2019
Takeda Completes Sale of Xiidra to Novartis
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its sale of its Xiidra® (lifitegrast ophthalmic solution) 5% product to Novartis for $3.4 billion upfront in cash and up to an additional $1.9 billion in potential milestone payments.
July 2, 2019
Sanofi cleared with “if” to market Libtayo in Europe
The European Commission (EC) has granted conditional marketing authorization for Libtayo to treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation.
July 1, 2019
Oasmia changes CEO amid reporting suspicious transactions
Amid Oasmia’s decision to report certain suspicious transactions that has been made by to company during several years, to the Swedish authority, Sven Rohmann, has today been appointed as acting CEO of the company, to replace the present CEO, Mikael Asp.
July 1, 2019
Basilea starts new cohort in a study, testing derazantinib in iCCA
Basilea Pharmaceutica has enrolled the first patient in a newly opened cohort in the ongoing FIDES-01 phase 2 registrational study with the panFGFR kinase inhibitor derazantinib in intrahepatic cholangiocarcinoma (iCCA).
July 1, 2019
Smithers Avanza Names Frank M. Rotella Director of Operations at New Jersey Laboratory
New Jersey Expansion Broadens Service Portfolio Currently Offered in Maryland EWING, N.J.–(BUSINESS WIRE)–#NewJersey—Smithers Avanza, a contract research organization (CRO) supporting…
July 1, 2019
Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study
First clinical study of a rationally-defined bacterial consortium (VE416) for treating food allergy, will initially be studied in patients with history of peanut allergy